"MARKET SPIRAL PRICING OF CANCER DRUGS"
Companies are spiraling up high prices, not because of costs or better value, but because they can get away with it, only the USA.
Senior oncologist, Hagop Kantarjian, and I show that very high prices for cancer & specialty drugs are not due to high costs of research, nor to added clinical value. Companies are simply spiraling up prices already 2-3 times greater than other capitalist countries allow, because we allow them to.
High co-pays hurt patients and impede good clinical care.
This exploitation of serious ill patients and taxpayers is ethically troubling and must stop.